Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semax

ACTH(4-10) analogue, Heptapeptide SEMAX

Quick Stats
Studies 172
Trials 37
Score 3
2006 pubmed

[Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation].

Zolotarev. Iu A IuA; Dadaian. A K AK; Dolotov. O V OV; Kozik. V S VS; Kost. N V NV; Sokolov. O Iu OIu; Dorokhova. E M EM; Meshavkin. V K VK; Inozemtseva. L S LS; Gabaeva. M V MV; Andreeva. L A LA; Alfeeva. L Iu LIu; Pavlov. T S TS; Badmaeva. K E KE; Badmaeva. S E SE; Bakaeva. Z V ZV; Kopylova. G N GN; Samonina. G E GE; Vas'kovskiĭ. B V BV; Grivennikov. I A IA; Zozulia. A A AA; Miasoedov. N F NF

Key Findings

  • Intranasal Semax reaches brain tissue and is metabolized mainly into the pentapeptide HFPGP and the tripeptide PGP.
  • Semax exhibits a high inhibitory effect on blood plasma enkephalinases, acting primarily on aminopeptidases.
  • The tritium‑labeling method allows precise measurement of both the parent peptide and its degradation products in vivo.

Practical Outcomes

  • For self‑experimenters, the data suggest that nasal dosing of Semax can deliver the active peptide to the brain, but it will be quickly broken down into smaller fragments. The strong inhibition of enkephalinases may enhance endogenous opioid signaling, which could influence mood, stress response, or pain perception. When planning protocols, consider using doses that maintain measurable brain levels for the desired duration and be aware that rapid metabolism may limit long‑term effects without repeated dosing.

Summary

The study used specially labeled versions of the peptide Semax to track how it breaks down in the body and how it affects enzymes that break down natural brain chemicals. It showed that after nasal delivery, Semax reaches the brain and is mainly split into smaller pieces (HFPGP and PGP). Importantly, Semax strongly blocks certain blood enzymes (enkephalinases) that normally degrade opioid-like peptides, mainly by acting on aminopeptidases.

Abstract

Biologically active peptides evenly labeled with tritium were used for studying the in vitro and in vivo biodegradation of the peptides. Tritium-labeled peptides with a specific radioactivity of 50-150 Ci/mmol were obtained by high temperature solid phase catalytic isotope exchange (HSCIE) with spillover tritium. The distribution of the isotope label among all amino acid residues of these peptides allows the simultaneous determination of practically all possible products of their enzymatic hydrolysis. The developed analytical method includes extraction of tritium-labeled peptides from organism tissues and chromatographic isolation of individual labeled peptides from the mixture of degradation products. The concentrations of a peptide under study and the products of its biodegradation were calculated from the results of liquid scintillation counting. This approach was used for studying the pathways of biodegradation of the heptapeptide TKPRPGP (Selank) and the tripeptide PGP in blood plasma. The pharmacokinetics of Selank, an anxiolytic peptide, was also studied in brain tissues using the intranasal in vivo administration of this peptide. The concentrations of labeled peptides were determined, and the pentapeptide TKPRP, tripeptide TKP, and dipeptides RP and GP were shown to be the major products of Selank biodegradation. The study of the biodegradation of the heptapeptide MEHFPGP (Semax) in the presence of nerve cells showed that the major products of its biodegradation are the pentapeptide HFPGP and tripeptide PGP. The enkephalinase activity of blood plasma was studied with the use of evenly tritium-labeled [Leu]enkephalin. A high inhibitory effect of Semax on blood plasma enkephalinases was shown to arise from its action on aminopeptidases. The method, based on the use of evenly tritium-labeled peptides, allows the determination of peptide concentrations and the activity of enzymes involved in their degradation on a tg scale of biological samples both in vitro and in vivo.

Study Information

Provider

pubmed

Year

2006